TY - JOUR
T1 - P2y purinergic receptors, endothelial dysfunction, and cardiovascular diseases
AU - Strassheim, Derek
AU - Verin, Alexander
AU - Batori, Robert
AU - Nijmeh, Hala
AU - Burns, Nana
AU - Kovacs-Kasa, Anita
AU - Umapathy, Nagavedi S.
AU - Kotamarthi, Janavi
AU - Gokhale, Yash S.
AU - Karoor, Vijaya
AU - Stenmark, Kurt R.
AU - Gerasimovskaya, Evgenia
N1 - Funding Information:
Program Project Grant HL101902 (AV), and the AHA Grant AHA00161 (A.K.). Conflicts of Interest: The authors declare no conflict of interest. Conflicts of Interest: The authors declare no conflict of interest.
Funding Information:
Funding: This work was supported by the National Institute of Health R01 HL086783 (E.G.), PPG-HL-14985 (K.R.S), the American Heart Association (AHA) Postdoctoral Fellowship 20POST35210753 (R.B.), the NHLBI
Funding Information:
This work was supported by the National Institute of HealthR01 HL086783 (E.G.), PPG-HL-14985 (K.R.S), the American Heart Association (AHA) Postdoctoral Fellowship 20POST35210753 (R.B.), the NHLBI Program Project Grant HL101902 (A.V.), and the AHA Grant AHA00161 (A.K.).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9/2
Y1 - 2020/9/2
N2 - Purinergic G-protein-coupled receptors are ancient and the most abundant group of G-protein-coupled receptors (GPCRs). The wide distribution of purinergic receptors in the cardiovascular system, together with the expression of multiple receptor subtypes in endothelial cells (ECs) and other vascular cells demonstrates the physiological importance of the purinergic signaling system in the regulation of the cardiovascular system. This review discusses the contribution of purinergic P2Y receptors to endothelial dysfunction (ED) in numerous cardiovascular diseases (CVDs). Endothelial dysfunction can be defined as a shift from a “calm” or non-activated state, characterized by low permeability, anti-thrombotic, and anti-inflammatory properties, to a “activated” state, characterized by vasoconstriction and increased permeability, pro-thrombotic, and pro-inflammatory properties. This state of ED is observed in many diseases, including atherosclerosis, diabetes, hypertension, metabolic syndrome, sepsis, and pulmonary hypertension. Herein, we review the recent advances in P2Y receptor physiology and emphasize some of their unique signaling features in pulmonary endothelial cells.
AB - Purinergic G-protein-coupled receptors are ancient and the most abundant group of G-protein-coupled receptors (GPCRs). The wide distribution of purinergic receptors in the cardiovascular system, together with the expression of multiple receptor subtypes in endothelial cells (ECs) and other vascular cells demonstrates the physiological importance of the purinergic signaling system in the regulation of the cardiovascular system. This review discusses the contribution of purinergic P2Y receptors to endothelial dysfunction (ED) in numerous cardiovascular diseases (CVDs). Endothelial dysfunction can be defined as a shift from a “calm” or non-activated state, characterized by low permeability, anti-thrombotic, and anti-inflammatory properties, to a “activated” state, characterized by vasoconstriction and increased permeability, pro-thrombotic, and pro-inflammatory properties. This state of ED is observed in many diseases, including atherosclerosis, diabetes, hypertension, metabolic syndrome, sepsis, and pulmonary hypertension. Herein, we review the recent advances in P2Y receptor physiology and emphasize some of their unique signaling features in pulmonary endothelial cells.
KW - Angiogenesis
KW - Cardiovascular diseases
KW - Endothelial cells
KW - Endothelial dysfunction
KW - Intracellular signaling
KW - Purinergic P2Y receptors
KW - Vasa vasorum
KW - Vascular injury
KW - Vascular permeability
KW - Vasoconstriction/vasodilation
UR - http://www.scopus.com/inward/record.url?scp=85091602685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091602685&partnerID=8YFLogxK
U2 - 10.3390/ijms21186855
DO - 10.3390/ijms21186855
M3 - Review article
C2 - 32962005
AN - SCOPUS:85091602685
SN - 1661-6596
VL - 21
SP - 1
EP - 21
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 18
M1 - 6855
ER -